|
Market Closed -
Australian S.E.
14:10:18 18/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 10.36 AUD | +5.82% |
|
+6.69% | -16.85% |
| Market Cap | 522M 371M 321M 301M 274M 515M 35.52B 3.53B 1.38B 17.8B 1.39B 1.36B 59.2B | P/E 2026 * |
13.8x | P/E 2027 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise Value | 270M 192M 166M 155M 141M 266M 18.34B 1.82B 714M 9.19B 720M 705M 30.56B | EV / Sales 2026 * |
2.72x | EV / Sales 2027 * | 2.27x |
| Free-Float |
83.79% | Yield 2026 * |
0.62% | Yield 2027 * | 0.82% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +5.82% | ||
| 1 week | +6.69% | ||
| Current month | +14.35% | ||
| 1 month | +1.17% | ||
| 3 months | +13.47% | ||
| 6 months | -5.99% | ||
| Current year | -16.85% |
| 1 week | 9.33 |  | 10.41 |
| 1 month | 8.77 | | 10.42 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.95 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 3/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 27/11/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 27/11/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.82% | +6.69% | -15.84% | -49.83% | 351M | |
| +1.25% | +2.06% | +41.74% | +0.13% | 80.48B | |
| -1.02% | -1.34% | -2.54% | +30.42% | 50.63B | |
| 0.00% | -4.73% | +10.26% | +167.70% | 47.57B | |
| +17.25% | +14.09% | -41.83% | -41.67% | 45.84B | |
| +1.27% | +3.98% | +55.99% | -18.82% | 30.9B | |
| -1.29% | +5.43% | +127.34% | -37.16% | 25.73B | |
| +0.37% | +2.60% | +46.27% | +93.96% | 25.03B | |
| +1.36% | +1.15% | -5.15% | +207.31% | 21.16B | |
| +1.49% | +5.30% | +65.41% | +127.40% | 16.75B | |
| Average | +2.71% | +0.59% | +28.16% | +47.94% | 34.44B | |
| Weighted average by Cap. | +2.69% | -0.10% | +25.98% | +43.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.21M 70.54M 60.9M 57.13M 52.04M 97.85M 6.74B 670M 262M 3.38B 265M 259M 11.24B | 105M 74.38M 64.21M 60.24M 54.87M 103M 7.11B 706M 277M 3.56B 279M 273M 11.85B |
| Net income | 35.72M 25.4M 21.93M 20.57M 18.74M 35.23M 2.43B 241M 94.5M 1.22B 95.36M 93.29M 4.05B | 37.66M 26.78M 23.12M 21.69M 19.75M 37.15M 2.56B 254M 99.63M 1.28B 101M 98.36M 4.27B |
| Net Debt | -253M -180M -155M -146M -133M -249M -17.18B -1.71B -669M -8.61B -675M -660M -28.63B | -285M -202M -175M -164M -149M -281M -19.35B -1.92B -753M -9.69B -760M -743M -32.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/08/26 | A$10.36 | +5.82% | 208,294 |
| 17/08/26 | A$9.790 | +2.51% | 87,880 |
| 14/08/26 | A$9.550 | -0.42% | 52,527 |
| 13/08/26 | A$9.590 | +0.95% | 78,621 |
| 12/08/26 | A$9.500 | -2.16% | 93,054 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
